Trial Profile
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thromboembolism; Venous thromboembolism
- Focus Therapeutic Use
- 08 Apr 2016 Results (n=22) published in the Journal of Thrombosis and Haemostasis.
- 24 Mar 2016 Status changed from recruiting to discontinued due to slow recruitment as reported by ClinicalTrials.gov.
- 01 Jan 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.